Online inquiry

IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14975MR)

This product GTTS-WQ14975MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL17A gene. The antibody can be applied in Diseases or disorders including airway inflammation research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605
UniProt ID Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ14975MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4616MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ13728MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RC48-0
GTTS-WQ6724MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA DS 1024
GTTS-WQ15075MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SSS-23
GTTS-WQ11897MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MLN-1202
GTTS-WQ10424MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY2439821
GTTS-WQ3472MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BA1126
GTTS-WQ5736MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CEA-IL-2v
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW